Gimme Care vs. Remedy Meds: prices, fine print, and the honest verdict

Tirzepatide pricing

Gimme Care offers tirzepatide without a published price we could capture. Remedy Meds: $399 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee.

Semaglutide pricing

Only Remedy Meds publishes a semaglutide price here: Semaglutide runs $299 a month all-in. Gimme Care offers semaglutide without a published price.

Transparency

Gimme Care: No price published (verified 2026-08-05); dispensing pharmacy not publicly named. Remedy Meds: Third-party-reported (verified 2026-08-05); dispensing pharmacy not publicly named. In this market, a named pharmacy and a dated, source-verified price are worth real money — they are what let you check the claim instead of trusting it.

Commitment & cancellation

Gimme Care: unknown; not published. Remedy Meds: unknown; not published.

Two ladders, side by side

Put both dose ladders on the same axis and the structures argue for themselves: Remedy Meds holds $399 on every rung (four-month titration: exactly $1,596). A flat ladder makes dose decisions purely clinical; a scaled one attaches an invoice to every escalation — including the post-plateau bump from 10 to 12.5 mg that many patients eventually face. Full framework: the titration cost guide.

The semaglutide board

Only Remedy Meds fields a verified semaglutide price here — $299/month all-in (#17 of 19) — while Gimme Care publishes no semaglutide figure we could capture. For a buyer starting on the cheaper molecule with a likely upgrade later, single-molecule programs mean a future re-shop; dual-molecule ones price the whole arc.

The five normalizations, applied to this pair

1 · All-in, not advertised. Gimme Care publishes no figure to normalize; Remedy Meds's ranked figure is $399, with no membership to add. 2 · Maintenance basis. Remedy Meds is dose-flat, so its entry and 10 mg figures coincide. 3 · Terms separated. Remedy Meds: standing $399, no prepaid tier — standing rates rank, prepaid effectives are labeled beside them. 4 · Evidence tiered. Gimme Care: no price published, read 2026-08-05; Remedy Meds: third-party-reported, read 2026-08-05. 5 · Pharmacy weighed. Gimme Care names no pharmacy; Remedy Meds names no pharmacy — in a pharmacy-variance market, disclosure is a scored asset. Run the same five on any roundup you read and most published “cheapest” lists reorder themselves.

Fine print, itemized

Gimme Care: no membership — the medication figure is the billed figure; not published; commitment: unknown. Remedy Meds: no membership — the medication figure is the billed figure; not published; commitment: unknown. The pattern to police on both sides is the same: memberships that outlive the medication order, renewal-relative cancellation deadlines, and prepaid terms whose refund language matters more than their discount in a year of live litigation. Cancel in writing; screenshot everything.

Transparency, audited

Gimme Care carries no price published pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Remedy Meds carries third-party-reported pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Our weighting is unapologetic: in a market of identical molecule names, a dated source-verified price and a named pharmacy are the two claims a buyer can actually check, and they carry 25 of 100 formula points between them — the methodology shows the math, and the pharmacy guide decodes every answer the five questions can return.

Switching between them

Moving from Gimme Care to Remedy Meds (or back) is administratively unglamorous: complete the new program's intake, let its prescriber issue a fresh prescription to its pharmacy, and cancel the old subscription in writing — prescriptions don't transfer between telehealth programs, and neither do prepaid balances, which is the quiet reason month-to-month terms are worth their premium.

Refills, shipping, and the week-to-week reality

The unglamorous layer — how the medication actually reaches you and stays on schedule — splits like this: Gimme Care: shipping unknown; consultation unknown. Remedy Meds: shipping included; consultation included. Cold-chain shipments run 3–7 days across the market; the recurring failure modes are refill-timing gaps and pharmacy backlogs, so whichever program wins here, order refills a week early and confirm the pharmacy’s current turnaround at intake.

Who should pick which

Pick Gimme Care if its published terms happen to fit your state, format, or timing. Pick Remedy Meds if you want a price that survives titration. Neither answer is universal — which is the argument for choosing from data with dates on it rather than from whichever ad loaded first.

What verification would take

For Gimme Care, ranking would require: any published price at all, on a page we can capture and date; the dose structure (flat or scaled, with the 10 mg tier stated); the pharmacy's name, 503A/503B status, and state licensure; commitment and cancellation terms verbatim. We publish the checklist because the gap is fixable — providers that clear it get ranked on the same arithmetic as everyone else, and readers who ask these questions get the answers this page can't yet print.

If neither one fits

The dataset's bench is deep; the closest verified third options to this matchup's price band are MEDVi at $399 (flat, no membership); Eden at $408 (dose-scaled, $99 membership included); Fridays at $359 (flat, no membership) — or skip straight to the rankings page, where every standard “cheapest / best / no-commitment” question is answered in one sourced sentence.

The brand benchmark both must beat

Neither program exists in a vacuum: FDA-approved Zepbound sits at $449/month at maintenance (LillyDirect or retail KwikPens, ~$350 on TrumpRx, ~$50 for newly eligible Medicare patients), and Wegovy at a flat $349. The cheaper of these two compounded options saves $600/year against the Zepbound benchmark — the number that has to justify accepting a not-FDA-reviewed product, per the full trade analysis. When a compounded quote drifts above ~$350, this benchmark starts winning the argument on its own.

The verdict

With incomplete published pricing on one or both sides, get current figures in writing before enrolling with either. Both records, with dates and sources, live in the pricing database.